{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T23:52:37Z","timestamp":1792453957310,"version":"4.5.0"},"reference-count":61,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T00:00:00Z","timestamp":1734566400000},"content-version":"am","delay-in-days":353,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.drudis.2023.103847","type":"journal-article","created":{"date-parts":[[2023,11,27]],"date-time":"2023-11-27T22:59:23Z","timestamp":1701125963000},"page":"103847","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Targeted degrader technologies as prospective SARS-CoV-2 therapies"],"prefix":"10.1016","volume":"29","author":[{"given":"Rabia","family":"Khurshid","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph M.","family":"Schulz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaming","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy S.","family":"Snowden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert C.","family":"Reynolds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan C.","family":"Sch\u00fcrer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2023.103847_b0005","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1136\/bmj.p1964","article-title":"Covid-19: scientists sound alarm over new BA.2.86 \u201cPirola\u201d variant","volume":"382","author":"Looi","year":"2023","journal-title":"Br Med J"},{"key":"10.1016\/j.drudis.2023.103847_b0010","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1001\/jama.2023.16498","article-title":"What to know about EG.5, the latest SARS-CoV-2 \u201cVariant of Interest\u201d","volume":"330","author":"Abbasi","year":"2023","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.drudis.2023.103847_b0015","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1136\/bmj.p1833","article-title":"Covid-19: hospital admissions rise in England amid fears of new variant and waning immunity","volume":"382","author":"Looi","year":"2023","journal-title":"Br Med J"},{"key":"10.1016\/j.drudis.2023.103847_b0020","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/s41586-020-2286-9","article-title":"A SARS-CoV-2 protein interaction map reveals targets for drug repurposing","volume":"583","author":"Gordon","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2023.103847_b0025","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1016\/j.drudis.2020.08.007","article-title":"Could PROTACs protect us from COVID-19?","volume":"25","author":"Martinez-Ortiz","year":"2020","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.drudis.2023.103847_b0030","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/s41392-022-00966-4","article-title":"Targeted protein degradation: mechanisms, strategies and application","volume":"7","author":"Zhao","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.drudis.2023.103847_b0035","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/s41573-019-0047-y","article-title":"Targeted protein degradation: expanding the toolbox","volume":"18","author":"Schapira","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.drudis.2023.103847_b0040","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1016\/j.cell.2017.10.033","article-title":"A method for the acute and rapid degradation of endogenous proteins","volume":"171","author":"Clift","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.drudis.2023.103847_b0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2022.105480","article-title":"Targeted protein degradation as an antiviral approach","volume":"210","author":"Chakravarty","year":"2023","journal-title":"Antiviral Res"},{"key":"10.1016\/j.drudis.2023.103847_b0050","article-title":"PROTAC targeting cyclophilin A controls virus-induced cytokine storm","volume":"26","author":"Li","year":"2023","journal-title":"iScience"},{"key":"10.1016\/j.drudis.2023.103847_b0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellin.2023.100092","article-title":"Antiviral PROTACs: opportunity borne with challenge","volume":"2","author":"Liang","year":"2023","journal-title":"Cell Insight"},{"key":"10.1016\/j.drudis.2023.103847_b0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115447","article-title":"Proteolysis-targeting chimeras in biotherapeutics: current trends and future applications","volume":"257","author":"Li","year":"2023","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.drudis.2023.103847_b0065","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/j.chembiol.2023.06.020","article-title":"The rise of degrader drugs","volume":"30","author":"Teng","year":"2023","journal-title":"Cell Chem Biol"},{"key":"10.1016\/j.drudis.2023.103847_b0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113814","article-title":"Indomethacin-based PROTACs as pan-coronavirus antiviral agents","volume":"226","author":"Desantis","year":"2021","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.drudis.2023.103847_b0075","doi-asserted-by":"crossref","first-page":"568","DOI":"10.3390\/v15020568","article-title":"Targeting human proteins for antiviral drug discovery and repurposing efforts: a focus on protein kinases","volume":"15","author":"Hajjo","year":"2023","journal-title":"Viruses"},{"key":"10.1016\/j.drudis.2023.103847_b0080","doi-asserted-by":"crossref","first-page":"181","DOI":"10.3389\/fonc.2013.00181","article-title":"COX-independent mechanisms of cancer chemoprevention by anti-inflammatory drugs","volume":"3","author":"Gurpinar","year":"2013","journal-title":"Front Oncol"},{"key":"10.1016\/j.drudis.2023.103847_b0085","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1038\/s41587-022-01381-4","article-title":"Generation of a live attenuated influenza A vaccine by proteolysis targeting","volume":"40","author":"Si","year":"2022","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.drudis.2023.103847_b0090","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1021\/acscentsci.0c00984","article-title":"Targeting the SARS-CoV-2 RNA genome with small molecule binders and ribonuclease targeting chimera (RIBOTAC) degraders","volume":"6","author":"Haniff","year":"2020","journal-title":"ACS Cent Sci"},{"key":"10.1016\/j.drudis.2023.103847_b0095","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1021\/acscentsci.3c00015","article-title":"Proximity-induced nucleic acid degrader (PINAD) approach to targeted RNA degradation using small molecules","volume":"9","author":"Mikutis","year":"2023","journal-title":"ACS Cent Sci"},{"key":"10.1016\/j.drudis.2023.103847_b0100","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1007\/s10930-020-09933-w","article-title":"An overview of the crystallized structures of the SARS-CoV-2","volume":"39","author":"Ionescu","year":"2020","journal-title":"Protein J"},{"key":"10.1016\/j.drudis.2023.103847_b0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.114367","article-title":"Paxlovid (Nirmatrelvir\/Ritonavir): a new approach to Covid-19 therapy?","volume":"162","author":"Hashemian","year":"2023","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.drudis.2023.103847_b0110","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.3390\/v13081585","article-title":"Non-nucleotide RNA-dependent RNA polymerase inhibitor that blocks SARS-CoV-2 replication","volume":"13","author":"Dejmek","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.drudis.2023.103847_b0115","doi-asserted-by":"crossref","first-page":"e21573","DOI":"10.1096\/fj.202100280RR","article-title":"Potential 3-chymotrypsin-like cysteine protease cleavage sites in the coronavirus polyproteins pp1a and pp1ab and their possible relevance to COVID-19 vaccine and drug development","volume":"35","author":"Yan","year":"2021","journal-title":"FASEB J"},{"key":"10.1016\/j.drudis.2023.103847_b0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2023.103727","article-title":"Analyzing 3D structures of the SARS-CoV-2 main protease reveals structural features of ligand binding for COVID-19 drug discovery","volume":"28","author":"Xu","year":"2023","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.drudis.2023.103847_b0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2023.103579","article-title":"COVID-19 therapeutics: small-molecule drug development targeting SARS-CoV-2 main protease","volume":"28","author":"Kronenberger","year":"2023","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.drudis.2023.103847_b0130","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1021\/acsptsci.0c00108","article-title":"Identification of SARS-CoV-2 3CL protease inhibitors by a quantitative high-throughput screening","volume":"3","author":"Zhu","year":"2020","journal-title":"ACS Pharmacol Transl Sci"},{"key":"10.1016\/j.drudis.2023.103847_b0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.tet.2020.131761","article-title":"Advances in developing small molecule SARS 3CL(pro) inhibitors as potential remedy for corona virus infection","volume":"77","author":"Konwar","year":"2021","journal-title":"Tetrahedron"},{"key":"10.1016\/j.drudis.2023.103847_b0140","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.2147\/DDDT.S359009","article-title":"Progress on SARS-CoV-2 3CLpro inhibitors: inspiration from SARS-CoV 3CLpro peptidomimetics and small-molecule anti-inflammatory compounds","volume":"16","author":"Zhu","year":"2022","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.drudis.2023.103847_b0145","article-title":"Structural basis for replicase polyprotein cleavage and substrate specificity of main protease from SARS-CoV-2","volume":"119","author":"Zhao","year":"2022","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.drudis.2023.103847_b0150","doi-asserted-by":"crossref","first-page":"eabe0751","DOI":"10.1126\/sciadv.abe0751","article-title":"Structure and inhibition of the SARS-CoV-2 main protease reveal strategy for developing dual inhibitors against M(pro) and cathepsin L","volume":"6","author":"Sacco","year":"2020","journal-title":"Sci Adv"},{"key":"10.1016\/j.drudis.2023.103847_b0155","doi-asserted-by":"crossref","first-page":"811","DOI":"10.3390\/v15030811","article-title":"Real-world experience of the comparative effectiveness and safety of Molnupiravir and Nirmatrelvir\/Ritonavir in high-risk patients with COVID-19 in a community setting","volume":"15","author":"Mutoh","year":"2023","journal-title":"Viruses"},{"key":"10.1016\/j.drudis.2023.103847_b0160","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1177\/10600280221133376","article-title":"Baricitinib versus tocilizumab for the treatment of moderate to severe COVID-19","volume":"57","author":"Reid","year":"2023","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.drudis.2023.103847_b0165","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0140-6736(21)02657-X","article-title":"Caution required with use of ritonavir-boosted PF-07321332 in COVID-19 management","volume":"399","author":"Heskin","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.drudis.2023.103847_b0170","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.3390\/microorganisms10071475","article-title":"The combination of molnupiravir with nirmatrelvir or GC376 has a synergic role in the inhibition of SARS-CoV-2 replication in vitro","volume":"10","author":"Gidari","year":"2022","journal-title":"Microorganisms"},{"key":"10.1016\/j.drudis.2023.103847_b0175","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/s41594-021-00651-0","article-title":"Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis","volume":"28","author":"Kabinger","year":"2021","journal-title":"Nat Struct Mol Biol"},{"key":"10.1016\/j.drudis.2023.103847_b0180","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abq4064","article-title":"S-217622, a SARS-CoV-2 main protease inhibitor, decreases viral load and ameliorates COVID-19 severity in hamsters","volume":"15","author":"Sasaki","year":"2023","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.drudis.2023.103847_b0185","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2022.872729","article-title":"Overcoming cancer drug resistance utilizing PROTAC technology","volume":"10","author":"Burke","year":"2022","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.drudis.2023.103847_b0190","article-title":"The binding mechanism of failed, in processing and succeed inhibitors target SARS-CoV-2 main protease","volume":"1\u201312","author":"Hongyu","year":"2023","journal-title":"J Biomol Struct Dyn"},{"key":"10.1016\/j.drudis.2023.103847_b0195","doi-asserted-by":"crossref","DOI":"10.3389\/fchem.2021.707317","article-title":"E3 ligase ligands in successful PROTACs: an overview of syntheses and linker attachment points","volume":"9","author":"Bricelj","year":"2021","journal-title":"Front Chem"},{"key":"10.1016\/j.drudis.2023.103847_b0200","doi-asserted-by":"crossref","DOI":"10.3389\/fchem.2021.672267","article-title":"From conception to development: investigating PROTACs features for improved cell permeability and successful protein degradation","volume":"9","author":"Cecchini","year":"2021","journal-title":"Front Chem"},{"key":"10.1016\/j.drudis.2023.103847_b0205","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.2174\/092986711796150496","article-title":"Peptides or small molecules? Different approaches to develop more effective CDK inhibitors","volume":"18","author":"Cirillo","year":"2011","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.drudis.2023.103847_b0210","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s10989-006-9016-5","article-title":"Peptide, peptidomimetic, and small-molecule antagonists of the p53-HDM2 protein-protein interaction","volume":"12","author":"Fischer","year":"2006","journal-title":"Int J Pept Res Ther"},{"key":"10.1016\/j.drudis.2023.103847_b0215","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1126\/science.abf7945","article-title":"X-ray screening identifies active site and allosteric inhibitors of SARS-CoV-2 main protease","volume":"372","author":"Gunther","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.drudis.2023.103847_b0220","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/ddr.21406","article-title":"Limiting assumptions in the design of peptidomimetics","volume":"78","author":"Marshall","year":"2017","journal-title":"Drug Dev Res"},{"key":"10.1016\/j.drudis.2023.103847_b0225","doi-asserted-by":"crossref","first-page":"11316","DOI":"10.1021\/jacs.0c05753","article-title":"Correction to efficient targeted degradation via reversible and irreversible covalent PROTACs","volume":"142","author":"Gabizon","year":"2020","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.drudis.2023.103847_b0230","doi-asserted-by":"crossref","first-page":"764","DOI":"10.3390\/jpm11080764","article-title":"Non-covalent BTK inhibitors-the new BTKids on the block for B-cell malignancies","volume":"11","author":"Lewis","year":"2021","journal-title":"J Pers Med"},{"key":"10.1016\/j.drudis.2023.103847_b0235","doi-asserted-by":"crossref","first-page":"e1800518","DOI":"10.1002\/cbdv.201800518","article-title":"Covalent vs. non-covalent inhibition: tackling drug resistance in EGFR - a thorough dynamic perspective","volume":"16","author":"Akher","year":"2019","journal-title":"Chem Biodivers"},{"key":"10.1016\/j.drudis.2023.103847_b0240","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.3390\/molecules20021984","article-title":"Theory and applications of covalent docking in drug discovery: merits and pitfalls","volume":"20","author":"Kumalo","year":"2015","journal-title":"Molecules"},{"key":"10.1016\/j.drudis.2023.103847_b0245","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1007\/s00044-023-03065-3","article-title":"An update on the discovery and development of reversible covalent inhibitors","volume":"32","author":"Faridoon","year":"2023","journal-title":"Med Chem Res"},{"key":"10.1016\/j.drudis.2023.103847_b0250","doi-asserted-by":"crossref","first-page":"3326","DOI":"10.1021\/acs.biochem.8b00315","article-title":"The Taxonomy of covalent inhibitors","volume":"57","author":"Tuley","year":"2018","journal-title":"Biochemistry"},{"key":"10.1016\/j.drudis.2023.103847_b0255","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1039\/D0MD00154F","article-title":"Covalent inhibitors: a rational approach to drug discovery","volume":"11","author":"Sutanto","year":"2020","journal-title":"RSC Med Chem"},{"key":"10.1016\/j.drudis.2023.103847_b0260","doi-asserted-by":"crossref","first-page":"11040","DOI":"10.1021\/acs.jmedchem.3c00221","article-title":"A systematic survey of reversibly covalent dipeptidyl inhibitors of the SARS-CoV-2 main protease","volume":"66","author":"Geng","year":"2023","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2023.103847_b0265","doi-asserted-by":"crossref","first-page":"12266","DOI":"10.1021\/acs.jmedchem.3c00818","article-title":"Discovery and mechanism study of SARS-CoV-2 3C-like protease inhibitors with a new reactive group","volume":"66","author":"Ren","year":"2023","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2023.103847_b0270","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1039\/C9CC08238G","article-title":"Protein degradation through covalent inhibitor-based PROTACs","volume":"56","author":"Xue","year":"2020","journal-title":"Chem Commun (Camb)"},{"key":"10.1016\/j.drudis.2023.103847_b0275","doi-asserted-by":"crossref","first-page":"2880","DOI":"10.1021\/acs.jmedchem.1c00598","article-title":"Structure-based optimization of ML300-derived, noncovalent inhibitors targeting the severe acute respiratory syndrome coronavirus 3CL protease (SARS-CoV-2 3CL(pro))","volume":"65","author":"Han","year":"2022","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2023.103847_b0280","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1021\/acs.jcim.8b00872","article-title":"In silico modeling of PROTAC-mediated ternary complexes: validation and application","volume":"59","author":"Drummond","year":"2019","journal-title":"J Chem Inf Model"},{"key":"10.1016\/j.drudis.2023.103847_b0285","doi-asserted-by":"crossref","first-page":"5234","DOI":"10.1021\/acs.jcim.0c00897","article-title":"Improved accuracy for modeling PROTAC-mediated ternary complex formation and targeted protein degradation via new in silico methodologies","volume":"60","author":"Drummond","year":"2020","journal-title":"J Chem Inf Model"},{"key":"10.1016\/j.drudis.2023.103847_b0290","doi-asserted-by":"crossref","first-page":"4894","DOI":"10.1021\/acs.jcim.0c00589","article-title":"PRosetta C: Rosetta based modeling of PROTAC mediated ternary complexes","volume":"60","author":"Zaidman","year":"2020","journal-title":"J Chem Inf Model"},{"key":"10.1016\/j.drudis.2023.103847_b0295","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1021\/acsptsci.2c00089","article-title":"Novel design strategies to enhance the efficiency of proteolysis targeting chimeras","volume":"5","author":"Zhao","year":"2022","journal-title":"ACS Pharmacol Transl Sci"},{"key":"10.1016\/j.drudis.2023.103847_b0300","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2023.103643","article-title":"Industry perspective on the nonclinical safety assessment of heterobifunctional degraders","volume":"28","author":"Hemkens","year":"2023","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.drudis.2023.103847_b0305","doi-asserted-by":"crossref","first-page":"4066","DOI":"10.1021\/acs.jmedchem.5b00104","article-title":"pkCSM: predicting small-molecule pharmacokinetic and toxicity properties using graph-based signatures","volume":"58","author":"Pires","year":"2015","journal-title":"J Med Chem"}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S135964462300363X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S135964462300363X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T13:07:30Z","timestamp":1761224850000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S135964462300363X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":61,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S135964462300363X"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2023.103847","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeted degrader technologies as prospective SARS-CoV-2 therapies","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2023.103847","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103847"}}